

Claims:

- 5 1. A combined agent, said agent comprising *cis*-hydroxyproline
 (CHP) and gemcitabine.
2. The agent according to claim 1,
 characterized in that
10 it comprises a pharmaceutically acceptable carrier, adju-
 vant and/or vehicle.
3. The agent according to claim 2,
 characterized in that
15 the carrier is selected from the group comprising fillers,
 diluents, binders, humectants, disintegrants, dissolution
 retarders, absorption enhancers, wetting agents, adsorb-
 ents and/or lubricants.
- 20 4. The agent according to claim 2,
 characterized in that
 the vehicles are selected from the group comprising lipo-
 somes, siosomes and/or niosomes.
- 25 5. The agent according to any of claims 1 to 4,
 characterized in that
 the agent is a gel, poudrage, powder, infusion solution,
 tablet, sustained-release tablet, premix, a prodrug, emul-
 sion, brew-up formulation, drops, a concentrate, granu-
30 late, syrup, pellet, bolus, capsule, aerosol, spray and/or
 inhalant.
6. The agent according to claim 5,
 characterized in that

CHP and gemcitabine are present in a formulation at a concentration of 0.1 to 99.5, preferably 0.5 to 95, and more preferably 20 to 80 wt.-%.

5 7. The agent according to any of claims 1 to 6,
characterized in that
CHP and gemcitabine are present in said formulation at a
ratio of from 500:1 to 1:500, preferably from 100:1 to
1:100, and more preferably from 50:1 to 1:50.

10 8. An anti-tumor agent,
characterized in that
it comprises a combined agent according to any of claims 1
to 7.

15 9. Use of the agent according to any of claims 1 to 8 in the
prophylaxis, therapy, follow-up and/or aftercare of dis-
eases associated with cell growth, cell differentiation
and/or cell division.

20 10. The use according to the preceding claim,
characterized in that
the disease is a tumor.

25 11. The use according to claim 9 or 10,
characterized in that
tumor growth, tumor spreading, tumor angiogenesis, tumor
invasion, tumor infiltration and/or tumor metastasization
are inhibited or prevented.

30 12. The use according to the preceding claim,
characterized in that

the tumor diseases are selected from the group of neoplastic tumors, inflammatory tumors and/or abscesses, effusions and/or edemas.

- 5 13. The use according to any of claims 10 to 12,
characterized in that
the tumor is a solid tumor or a leukemia.
- 10 14. The use according to the preceding claim,
characterized in that
the solid tumor is a tumor of the urogenital tract and/or
gastrointestinal tract.
- 15 15. The use according to any of claims 10 to 14,
characterized in that
the tumor is a colon carcinoma, stomach carcinoma, pan-
creas carcinoma, small intestine carcinoma, ovarian carci-
noma, cervical carcinoma, lung carcinoma, prostate carci-
noma, mammary carcinoma, renal cell carcinoma, a brain tu-
20 mor, head-throat tumor, liver carcinoma, and/or a metas-
tase of the above tumors.
- 25 16. The use according to claim 13 or 14,
characterized in that
the solid tumor is a mammary, bronchial, colorectal,
and/or prostate carcinoma and/or a metastase of the above
tumors.
- 30 17. The use according to claim 14,
characterized in that
the tumor of the urogenital tract is a bladder carcinoma
and/or a metastase of such tumors.
18. The use according to any of claims 9 to 17,

characterized in that
said follow-up is monitoring the effectiveness of an anti-tumor treatment.

5 19. The use according to any of claims 9 to 18,
characterized in that
the agents according to claims 1 to 8 are employed in the
prophylaxis, prevention, diagnosis, attenuation, therapy,
follow-up and/or aftercare of tumor metastasization, tumor
10 invasion, tumor growth, tumor spreading, tumor infiltra-
tion and/or tumor angiogenesis.

20. The use according to any of claims 9 to 19,
characterized in that
15 said follow-up is monitoring the effectiveness of an anti-tumor treatment.

21. The use according to any of claims 9 to 20,
characterized in that
20 the agents according to claims 1 to 8 are used in a combined therapy.

22. The use according to the preceding claim,
characterized in that
25 said combined therapy comprises a chemotherapy, a treatment with cytostatic agents and/or a radiotherapy.

23. The use according to the preceding claim,
characterized in that
30 the combined therapy comprises an adjuvant, biologically specified form of therapy.

24. The use according to the preceding claim,
characterized in that

said form of therapy is an immune therapy.

25. The use according to any of claims 9 to 24 to increase the
sensitivity of tumor cells to cytostatic agents and/or ra-
diation.

26. The use according to any of claims 9 to 25 for inhibiting
the viability, the proliferation rate of cells, for induc-
ing apoptosis and/or cell cycle arrest.

27. The use according to any of claims 9 to 26,
characterized in that
the preparation is employed orally, vaginally, rectally,
nasally, subcutaneously, intravenously, intramuscularly,
intraperitoneally, regionally and/or topically.

28. The use according to any of claims 9 to 27,
characterized in that
the agents according to claims 1 to 8 are employed in
overall amounts of from 0.05 to 1000 mg per kg, preferably
from 5 to 450 mg per kg body weight per 24 hours.